Artivion (NYSE:AORT) Reaches New 52-Week High at $25.55

Shares of Artivion, Inc. (NYSE:AORT) reached a new 52-week high on Friday . The company traded as high as $25.55 and last traded at $25.43, with a volume of 83740 shares trading hands. The stock had previously closed at $24.85.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Stifel Nicolaus increased their price target on Artivion from $22.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Needham & Company LLC raised their price objective on Artivion from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, May 7th.

Artivion Price Performance

The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -106.88 and a beta of 1.72. The company has a current ratio of 6.04, a quick ratio of 4.26 and a debt-to-equity ratio of 1.07. The company has a 50 day moving average of $22.81 and a 200 day moving average of $20.28.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Monday, May 6th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.02 by $0.04. The business had revenue of $97.43 million for the quarter, compared to the consensus estimate of $92.30 million. Artivion had a positive return on equity of 3.64% and a negative net margin of 2.61%. Equities research analysts predict that Artivion, Inc. will post 0.24 EPS for the current fiscal year.

Hedge Funds Weigh In On Artivion

A number of large investors have recently added to or reduced their stakes in the company. Tidal Investments LLC bought a new position in Artivion during the 1st quarter worth about $257,000. Price T Rowe Associates Inc. MD increased its position in shares of Artivion by 5.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 33,690 shares of the company’s stock valued at $713,000 after acquiring an additional 1,634 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its position in shares of Artivion by 7.9% in the first quarter. CANADA LIFE ASSURANCE Co now owns 34,461 shares of the company’s stock valued at $729,000 after acquiring an additional 2,531 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Artivion by 1.3% in the first quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock valued at $56,388,000 after acquiring an additional 33,982 shares during the last quarter. Finally, First Eagle Investment Management LLC increased its position in shares of Artivion by 8.1% in the first quarter. First Eagle Investment Management LLC now owns 570,242 shares of the company’s stock valued at $12,066,000 after acquiring an additional 42,705 shares during the last quarter. Institutional investors own 86.37% of the company’s stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.